A recent report describes the case of a 47-year-old male patient who experienced eosinophilic gastritis secondary to proton pump inhibitor (PPI) administration and highlights the importance of increasing awareness of this potential hypersensitivity reaction.
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease (ESRD) and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).
The investigational treatment inclisiran (The Medicines Company) was associated with a sustained reduction in low density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents and elevated LDL-C despite maximum tolerated doses of LDL-C lowering therapies.
Investigators assessed the efficacy and safety of pulmonary vasodilators to treat pediatric pulmonary arterial hypertension.
The National Lipid Association (NLA) has released updated guidance for clinicians on identifying patients for which proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor therapy would provide reasonable value. Currently, two PCSK9 therapies have been approved by the Food and Drug Administration. Alirocumab is indicated as an adjunct to diet, alone or in combination with…
Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source
The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.
Risks reduced for total cardiovascular disease events, CVD death, coronary heart disease, and stroke
A first-in-class artificial intelligence-based solution that enables healthcare professionals to detect heart murmurs on a personal mobile device has received clearance from the FDA.
AliveCor announced that the FDA has cleared a new iteration of their KardiaMobile device, the KardiaMobile 6L, the first 6-lead personal electrocardiogram (ECG) device.
